Pfizer To Buy Metsera As Novo Shares Rise
Pfizer to buy Metsera for up to $10 billion after a sweetened offer; FTC HSR warnings and litigation could delay closing and shift trader positioning.
KEY TAKEAWAYS
- Pfizer agreed to acquire Metsera for up to $10 billion after a sweetened offer.
- The deal will materially strengthen Pfizer's obesity drug portfolio and market position.
- FTC HSR warnings and Pfizer litigation pose material risks to closing and timing.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Pfizer Inc. (PFE) agreed to acquire Metsera after the company accepted a sweetened offer, and Novo Nordisk’s withdrawal on Nov. 8 over U.S. antitrust risks eased investor concern. The deal lifts Novo’s shares in early European trading on Nov. 10, 2025.
Pfizer Finalizes Deal to Acquire Metsera
Pfizer agreed to buy Metsera for up to $10 billion after Metsera accepted Pfizer’s improved offer late on Nov. 7, ending a competitive bidding process that included Novo Nordisk. Pfizer said the acquisition will significantly strengthen its obesity drug portfolio and enhance its market position. The transaction remains subject to regulatory approvals and customary closing conditions, including a vote by Metsera shareholders.
Regulatory Challenges and Litigation
On Nov. 9, the Federal Trade Commission warned Metsera and Novo Nordisk that their transaction structure could violate the Hart-Scott-Rodino (HSR) Act and risk “gun jumping,” potentially leading to unwinding, refunds, and civil penalties. Novo Nordisk withdrew its competing bid on Nov. 8, citing these antitrust concerns. The withdrawal preceded a 3.5% rise in Novo’s shares in early European trading on Nov. 10.
Pfizer has filed lawsuits against Metsera, its board, and Novo Nordisk in Delaware Chancery Court and federal antitrust court, alleging breach of contractual obligations and antitrust violations. These legal actions, combined with regulatory scrutiny, pose material risks to the deal’s timing and structure, which will affect when Pfizer can realize the acquisition’s strategic benefits.
